drugset / Trial / NCT06879327
Infant Malaria Vaccine Schedule Optimization
Phase 2
Active not recruiting
975 enrolled
PATH
Agilis · collabCERBA · collabChristian Medical College, Vellore, India · collabCytespace · collabMCT-CRO · collabPharmassist Ltd · collabSerum Institute of India Pvt. Ltd. · collabUniversity College London - Institute of Child Health (UCL-ICH) · collabVisMederi srl, Sienna, Italy · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.
Timeline
- Start
- 2025-05-30
- Primary completion
- 2027-10-18
- Completion
- 2027-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | R21 Matrix-M | Vaccine | 0.5 ml | Intramuscular |
| Background | Hexavalent vaccine | Vaccine | 0.5 ml | Intramuscular |
| Background | Measles and Rubella Vaccine | Vaccine | 0.5 ml | Subcutaneous |
| Background | Meningococcal (A, C, Y, W, X) polysaccharide conjugate vaccine | Vaccine | 0.5 ml | Intramuscular |
| Background | Pneumococcal Polysaccharide Conjugate Vaccine | Vaccine | 0.5 ml | Intramuscular |
| Background | Rotavirus, Live Attenuated (Oral) Vaccine | Vaccine | 2 ml | Oral |
| Background | Typhoid Conjugate vaccine | Vaccine | — | — |
| Background | Yellow Fever Vaccine | Vaccine | — | — |